Olin Biology stated during the survey that the company is actively advancing the progress of Phase III clinical trials of recombinant pneumococcal vaccines. As of mid-August 2024, the company has recruited approximately 4,100 cases for Phase III clinical trials of recombinant pneumococcal vaccines. Based on the current recruitment rate, it is expected to complete all enrollments in the first half of next year.
欧林生物：重组金葡菌疫苗III期临床试验预计明年上半年能够完成全部入组
Olin Biotech: It is expected that the phase III clinical trial of the recombinant golden staphylococcus vaccine will be able to complete all enrollments in the first half of next year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated